Publications
Detailed Information
The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yang, H. | - |
dc.contributor.author | Cho, N. -H. | - |
dc.contributor.author | Seong, S. -Y. | - |
dc.date.accessioned | 2012-07-03T02:18:05Z | - |
dc.date.available | 2012-07-03T02:18:05Z | - |
dc.date.issued | 2009-11 | - |
dc.identifier.citation | CLINICAL AND EXPERIMENTAL IMMUNOLOGY; Vol.158 2; 174-185 | ko_KR |
dc.identifier.issn | 0009-9104 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78191 | - |
dc.description.abstract | P>Mucin antigen 1 (MUC1) is overexpressed on various human adenocarcinomas and haematological malignancies and has long been used as a target antigen for cancer immunotherapy. Most of the preclinical and clinical studies using MUC1 have used the tandem repeat region of MUC1, which could be presented by only a limited set of major histocompatibility complex haplotypes. Here, we evaluated N-terminal region (2-147 amino acids) of MUC1 (MUC1-N) for dendritic cell (DC)-based cancer immunotherapy. We used Esherichia coli-derived MUC1-N that was fused to the protein transduction domain of human immunodeficiency virus Tat protein for three reasons. First, mature DCs do not phagocytose soluble protein antigens. Secondly, tumour cells express underglycosylated MUC1, which can generate epitopes repertoire that differs from normal cells, which express hyperglycosylated MUC1. Finally, aberrantly glycosylated MUC1 has been known to impair DC function. In our study, Tat-MUC1-N-loaded DCs induced type 1 T cell responses as well as cytotoxic T lymphocytes efficiently. Furthermore, they could break tolerance in the transgenic breast tumour mouse model, where MUC1-positive breast cancers grow spontaneously. Compared with DCs pulsed with unconjugated MUC1-N, DCs loaded with Tat-conjugated MUC1-N could delay tumour growth more effectively in the transgenic tumour model as well as in the tumour injection model. These results suggest that the recombinant N-terminal part of MUC1, which may provide a diverse epitope repertoire, could be utilized as an effective tumour antigen for DC-based cancer immunotherapy. | ko_KR |
dc.description.sponsorship | This work was supported by a grant of the Korea Healthcare
technology R&D Project, theMinistry of Health andWelfare, Republic of Korea (grant A062260) and theNationalResearch Foundation of Korea through the Pioneer Research Center Program funded by the Ministry of Education, Science and Technology (M10711160001-08M1116-00110). | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | WILEY-BLACKWELL PUBLISHING, INC | ko_KR |
dc.subject | cancer immunotherapy | ko_KR |
dc.subject | HIV Tat | ko_KR |
dc.subject | DC | ko_KR |
dc.subject | mucin antigen 1 | ko_KR |
dc.subject | protein transduction domain | ko_KR |
dc.title | The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours | ko_KR |
dc.type | Article | ko_KR |
dc.identifier.doi | 10.1111/j.1365-2249.2009.03997.x | - |
dc.citation.journaltitle | CLINICAL AND EXPERIMENTAL IMMUNOLOGY | - |
dc.description.citedreference | Bae MY, 2009, CLIN EXP IMMUNOL, V157, P128, DOI 10.1111/j.1365-2249.2009.03943.x | - |
dc.description.citedreference | Melief CJM, 2008, IMMUNITY, V29, P372, DOI 10.1016/j.immuni.2008.08.004 | - |
dc.description.citedreference | Tang CK, 2008, EXPERT REV VACCINES, V7, P951, DOI 10.1586/14760584.7.7.951 | - |
dc.description.citedreference | Tang CK, 2008, EXPERT REV VACCINES, V7, P963, DOI 10.1586/14760584.7.7.963 | - |
dc.description.citedreference | Sarkar K, 2008, VACCINE, V26, P4352, DOI 10.1016/j.vaccine.2008.06.048 | - |
dc.description.citedreference | Agata N, 2008, CANCER RES, V68, P6136, DOI 10.1158/0008-5472.CAN-08-0464 | - |
dc.description.citedreference | Palucka AK, 2007, IMMUNOL REV, V220, P129, DOI 10.1111/j.1600-065X.2007.00575.x | - |
dc.description.citedreference | Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661 | - |
dc.description.citedreference | Day EB, 2007, J IMMUNOL, V179, P2187 | - |
dc.description.citedreference | Ninkovic T, 2007, J IMMUNOL, V179, P2380 | - |
dc.description.citedreference | Gilboa E, 2007, J CLIN INVEST, V117, P1195, DOI 10.1172/JCI31205 | - |
dc.description.citedreference | Carraway KL, 2007, CURR TOP DEV BIOL, V78, P1, DOI 10.1016/S0070-2153(06)78001-2 | - |
dc.description.citedreference | Apostolopoulos V, 2006, VACCINE, V24, P3191, DOI 10.1016/j.vaccine.2006.01.032 | - |
dc.description.citedreference | Usharauli David, 2006, Nat Protoc, V1, P672, DOI 10.1038/nprot.2006.107 | - |
dc.description.citedreference | Yamamoto K, 2005, ANTICANCER RES, V25, P3575 | - |
dc.description.citedreference | Hanisch FG, 2005, BIOCHEM SOC T, V33, P705 | - |
dc.description.citedreference | Rughetti A, 2005, J IMMUNOL, V174, P7764 | - |
dc.description.citedreference | Viehl CT, 2005, BREAST CANCER RES TR, V91, P271, DOI 10.1007/s10549-005-0450-4 | - |
dc.description.citedreference | Kohlgraf KG, 2004, CANCER IMMUNOL IMMUN, V53, P1068, DOI 10.1007/s00262-004-0557-1 | - |
dc.description.citedreference | Figdor CG, 2004, NAT MED, V10, P475, DOI 10.1038/nm1039 | - |
dc.description.citedreference | Maraskovsky E, 2004, CLIN CANCER RES, V10, P2879, DOI 10.1158/1078-0432.CCR-03-0245 | - |
dc.description.citedreference | Kontani K, 2003, INT J MOL MED, V12, P493 | - |
dc.description.citedreference | Homma S, 2003, J GASTROENTEROL, V38, P989, DOI 10.1007/s00535-002-1183-3 | - |
dc.description.citedreference | Chen DS, 2003, IMMUNOLOGY, V109, P300, DOI 10.1046/j.1365-2567.2003.01656.x | - |
dc.description.citedreference | O`Rourke MGE, 2003, CANCER IMMUNOL IMMUN, V52, P387, DOI 10.1007/s00262-003-0375-x | - |
dc.description.citedreference | Shibagaki N, 2003, EUR J IMMUNOL, V33, P850, DOI 10.1002/eji.200323709 | - |
dc.description.citedreference | Morse MA, 2003, CANCER INVEST, V21, P341, DOI 10.1081/CNV-120018224 | - |
dc.description.citedreference | Mukherjee P, 2003, J IMMUNOTHER, V26, P47, DOI 10.1097/00002371-200301000-00006 | - |
dc.description.citedreference | Werdelin O, 2002, P NATL ACAD SCI USA, V99, P9611, DOI 10.1073/pnas.152345899 | - |
dc.description.citedreference | Wang HY, 2002, J CLIN INVEST, V109, P1463, DOI 10.1172/JCI200215399 | - |
dc.description.citedreference | Shibagaki N, 2002, J IMMUNOL, V168, P2393 | - |
dc.description.citedreference | Ciborowski P, 2002, CLIN EXP METASTAS, V19, P339, DOI 10.1023/A:1015590515957 | - |
dc.description.citedreference | Heukamp LC, 2002, J IMMUNOTHER, V25, P46, DOI 10.1097/00002371-200201000-00005 | - |
dc.description.citedreference | Hanisch FA, 2001, BIOL CHEM, V382, P143, DOI 10.1515/BC.2001.022 | - |
dc.description.citedreference | Heukamp LC, 2001, INT J CANCER, V91, P385, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1051>3.0.CO | - |
dc.description.citedreference | 2-Z | - |
dc.description.citedreference | Pietersz GA, 2000, VACCINE, V18, P2059, DOI 10.1016/S0264-410X(99)00515-0 | - |
dc.description.citedreference | Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7 | - |
dc.description.citedreference | Barratt-Boyes SM, 1999, CLIN CANCER RES, V5, P1918 | - |
dc.description.citedreference | Hiltbold EM, 1999, CELL IMMUNOL, V194, P143, DOI 10.1006/cimm.1999.1512 | - |
dc.description.citedreference | Speir JA, 1999, IMMUNITY, V10, P51, DOI 10.1016/S1074-7613(00)80006-0 | - |
dc.description.citedreference | Rieser C, 1999, UROL INT, V63, P151, DOI 10.1159/000030438 | - |
dc.description.citedreference | Glithero A, 1999, IMMUNITY, V10, P63, DOI 10.1016/S1074-7613(00)80007-2 | - |
dc.description.citedreference | Morse MA, 1998, CANCER RES, V58, P2965 | - |
dc.description.citedreference | GalliStampino L, 1997, CANCER RES, V57, P3214 | - |
dc.description.citedreference | DOMENECH N, 1995, J IMMUNOL, V155, P4766 | - |
dc.description.tc | 4 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.